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Study Objective: To directly compare perioperative morbidity and hospital stay after robotic-assisted
staging and laparotomy in patients with early stage endometrial endometrioid adenocarcinoma and
uterine weight under 480 g.
Design: Retrospective cohort study.
Setting: The West Clinic in Memphis, TN, USA.
Patients: Patients with Stage IA and Stage IB endometrial endometrioid adenocarcinoma and uterine
weight less than 480 g from June 2007 to January 2011.
Interventions: Patients underwent hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymph
node dissection with or without para-aortic lymph node dissection using robotic-assisted surgery or
open laparotomy.
Measurements: Perioperative complications and morbidity, length of hospital stay, progression-free
survival, overall survival, time to recurrence, and time do death from disease.
Main Results: A total of 160 patients who underwent laparotomy and 165 patients who received robotic-
assisted staging were identiﬁed. Compared with robotic-assisted staging, laparotomy was associated
with increased hospital stay (3 days vs. 1.4 days, p < 0.001), greater estimated blood loss (237 cm3 vs.
102 cm3, p < 0.001), larger uterine weight (136 g vs. 116 g, p < 0.001), as well as higher incidence of
postoperative complications [29.3% vs. 6.7%, odds ratio (OR) 5.82, 95% conﬁdence interval (CI) 2.1e11.7]
including postoperative ileus (9.0% vs. 1.0%, OR 7.82, 95% CI 1.7e35.0), wound infection (6.0% vs. 1.0%, OR
5.43, 95% CI 1.2e25.2), and postoperative atelectasis (4.0% vs. 0%, p < 0.01). There were no differences in
projected 5-year progression-free and overall survival rates.
Conclusion: Use of the daVinci robotic system was associated with less intraoperative blood loss, fewer
postoperative complications, and shorter hospital stay compared with laparotomy for patients with
uterine weight less than 480 g.
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for Gynecologic Endoscopy and MinimIntroduction
The daVinci robotic surgical system (Intuitive Surgical, Sunny-
vale, CA, USA) has had a signiﬁcant impact on minimally invasive
surgical staging for patients with gynecologic malignancies in theally Invasive Therapy. Published by Elsevier Taiwan LLC. All rights reserved.
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endometrial endometrioid adenocarcinoma have demonstrated
perioperative and survival outcomes comparable with previously
published data for laparoscopic-assisted and open surgical stag-
ing.2e4 Robotic-assisted surgical staging has been adopted by an
increasing number of providers as the standard approach for early
stage endometrial endometrioid adenocarcinoma.5 Robotic-
assisted staging is now widely used in private gynecologic
oncology practices,6 yet little data about outcomes in private cen-
ters exist.
Prior studies comparing laparotomy with minimally invasive
surgical techniques have included uterine weights > 500 g,7 which
is associated with an increase in perioperative complications.8 It
has been demonstrated that removing uteri < 480 g vaginally
following robotic-assisted hysterectomy with or without vaginal
morcellation is both feasible and safe.9 Given this, we aim to
directly compare perioperative outcomes following robotic-
assisted staging and laparotomy in patients with early stage
endometrial cancer and uterine weight < 480 g.
Materials and Methods
A retrospective chart review was performed for patients who
underwent surgical staging for Stage I endometrioid adenocarci-
noma of the uterus with postoperative uterine weight < 480 g at
the West Clinic from June 2007 to January 2011. The University of
Tennessee Health Science Center Institutional Review Board
approved this study. Chart review identiﬁed 326 patients for
analysis. Of these, 166 patients underwent robotic surgical staging
and 160 patients received staging by laparotomy. All staging was
revised to the International Federation of Gynecology and Obstet-
rics 2009 classiﬁcation. Bilateral pelvic lymph node dissection was
routinely performed following hysterectomy on all patients. All
patients were initially meant to undergo para-aortic lymph node
dissection. Obesity during robotic surgery limited para-aortic
lymph node dissection in some patients and was omitted. After
robotic-assisted or abdominal hysterectomy and bilateral salpingo-
oophorectomy were performed, pelvic and para-aortic lymphade-
nectomy was performed in accordance with the Gynecologic
Oncology Group Surgical Procedures Manual. Both the “S” and “Si”
models of the daVinci surgical systemwere used for robotic staging.
Lymph nodes were removed through the vagina using a stone
grasper. Uteri too large to be removed vaginally were transected
using curved Mayo scissors inside an Endo Catch bag (Covidien,
Mansﬁeld, MA, USA). Robotic vaginal cuff closure was performed
using 2-0 V-Loc (Covidien) in a running fashion. Vaginal cuff closure
during open laparotomy was performed using 2.0 VICRYL suture
(Ethicon, Cincinnati, OH, USA). Hospital and ofﬁce charts were
retrospectively reviewed for age, body mass index (BMI), estimated
blood loss (EBL), depth of myometrial invasion, lymphovascular
space invasion, stage, tumor grade, tumor size, uterine weight,
adjuvant therapy received, time to disease recurrence, recurrence
location, and postoperative complications. Postoperative compli-
cations were deﬁned as deep vein thrombosis, pulmonary embo-
lism, pneumonia, ileus, blood transfusion, wound infection, wound
evisceration, acute renal injury, atelectasis, and fever requiring
readmission within 30 days of surgery. Ileus was deﬁned as nausea
and/or emesis requiring nothing by mouth or nasogastric tube
placement beyond postoperative Day 2. Hemorrhage was deﬁned
as EBL> 500 cm3 or intraoperative or postoperative blood trans-
fusion within the ﬁrst 24 hours following surgery. Acute renal
injury was deﬁned as an increase in creatinine level by more than
two times the preoperative baseline. Statistical analysis using SAS
software (SAS Institute Inc., Cary, NC, USA) was performed using
Chi-square for discrete variables, t test for continuous variables, andKaplaneMeier curves for disease-free survival. All t tests were two
sided, and p < 0.05 was considered statistically signiﬁcant.
Results
Table 1 summarizes all patient demographic, surgical, and tu-
mor characteristics. A total 160 patients who underwent laparot-
omy and 166 patients who underwent robot-assisted staging for
both Stage IA and Stage IB endometrioid adenocarcinoma were
identiﬁed for analysis. There were no signiﬁcant differences in age
(p ¼ 0.686), BMI (p ¼ 0.165), or tumor size (p ¼ 0.427) between the
two cohorts. Signiﬁcantly more pelvic (mean 8.7 ± 7.4 vs. 6.4 ± 4.2,
p ¼ 0.001) and para-aortic lymph nodes (mean 1.6 ± 2.3 vs.
0.95 ± 1.8, p ¼ 0.006) were sampled using laparotomy. Uterine
weight was larger for the laparotomy cohort (mean 136 ± 72 g vs.
116 ± 61 g, p ¼ 0.001). EBL was higher in patients who underwent
laparotomy (mean 237 ± 221 mL vs. 102 ± 103 mL, p < 0.001). Pa-
tients stayed longer in the hospital following laparotomy than after
robotic-assisted staging (3 ± 1.8 days vs. 1.4 ± 1.2 days, p < 0.0001).
Our conversion rate from robotic-assisted staging to laparotomy
was 3.6% (3 for large uterine size,1 for obesity,1 for poor pulmonary
function in the Trendelenburg position, and 1 for adhesive disease).
There were no differences in stage (p ¼ 0.723), tumor grade
(p ¼ 0.98), or presence of lymphatic/vascular space invasion
(p ¼ 0.207). When comparing those with intermediate risk factors
(i.e., Grade 2/3, advanced age, outer third myometrial invasion, or
lymphovascular space involvement) there was no difference be-
tween the cohorts (p ¼ 0.966). One patient who underwent lapa-
rotomy and two patients who underwent robotic-assisted staging
received adjuvant carboplatin and taxol with concurrent brachy-
therapy (p ¼ 0.56). There were signiﬁcantly more complications
following laparotomy [29.3% vs. 6.7%, odds ratio (OR) 5.82; 95%
conﬁdence interval (CI) 2.9e11.7]. Wound infections occurred more
frequently after laparotomy (6.0% vs. 1.0%, OR 5.43; 95% CI
1.2e25.2). There was one return to the operating room for
abdominal evisceration in the laparotomy cohort. No vaginal evis-
cerations occurred in either cohort. Postoperative ileus was more
common following laparotomy (1.0% vs. 9.0%, OR 7.82; 95% CI
1.7e35.0). Hemorrhagewasmore likely during laparotomy (4.0% vs.
1.0%, OR 3.73; 95% CI 0.8e18.2). There was no difference in venous
thromboembolism rates between the two cohorts (p ¼ 0.242;
Table 2). Recurrence rates were similar between laparotomy and
robotic-assisted staging (10 patients vs. 11 patients, p ¼ 0.879, 95%
CI 6.0e5.0). The average time to cancer recurrence was similar
following robotic-assisted staging and laparotomy (19.4 months
and 18.5 months, respectively; p ¼ 0.865, 95% CI 9.8e11.5) as was
average time to death from endometrial cancer (23.9 months and
22.1 months, respectively; p ¼ 0.704, 95% CI 8.9e12.5). There was
no difference in disease-related deaths between the two cohorts (4
after laparotomy and 3 following robotic-assisted staging, p ¼ 0.75;
95% CI 5.0e3.0; Table 3). There was no difference in projected 5-
year progression-free survival following surgical staging between
the two cohorts (p ¼ 0.811; Figure 1) or projected 5-year overall
survival (p ¼ 0.509; Figure 2). Sites of recurrence are shown in
Table 3. No port-site metastases were noted.
Discussion
Our goal was to directly compare perioperative outcomes for
early stage endometrioid adenocarcinoma following robotic-
assisted staging and laparotomy in our practice since implement-
ing the daVinci robotic surgical system. We desired to compare
outcomes in patients who could have been staged using either
surgical modality. Prior studies comparing outcomes following
hysterectomy and staging for endometrial cancer have included
Table 1
Patient demographics.
Open Robotic assisted p 95% CI
N Mean N Mean
Age (y) 160 64.3 ± 11.8 165 64.8 ± 11.6 0.686 3.1e2.1
BMI 160 35.5 ± 8.5 165 34.1 ± 9.8 0.166 0.6e3.4
Pelvic nodes sampled 160 8.7 ± 7.4 165 6.4 ± 4.2 <0.001 0.9e3.6
Aortic nodes sampled 160 1.6 ± 2.3 165 1 ± 1.8 0.006 0.2e1.1
Hospital stay (days) 113 3 ± 1.8 104 1.4 ± 1.2 <0.001 1.2e2.0
EBL (cc) 106 237 ± 221 123 102 ± 103 <0.001 88e181
Tumor size (cm) 159 2.5 ± 2.1 165 2.3 ± 1.9 0.427 0.28e0.66
Uterine weight (g) 160 136 ± 72 165 116 ± 61 0.009 4.8e33.9
Open Robotic assisted p
N % N %
Stage 0.763
IA 49 30.6 48 29.1
IB 111 69.4 117 70.9
Grade 0.981
1 105 66 110 67
2 40 25 40 24
3 15 9 15 9
Lymphovascular space invasion 5 3 10 6 0.207
Gynecologic Oncology Group 99 intermittent risk criteria 0.966
Low risk 98 61 100 61
Low intermittent risk 34 21 37 22
High intermittent risk 28 18 28 17
Adjuvant treatment received 24 15 17 10 0.202
Chemotherapy þ radiation 1 4 2 12 0.560
Radiation alone 23 96 15 88
BMI ¼ body mass index; CI ¼ conﬁdence interval; EBL ¼ estimated blood loss.
Table 2
Perioperative complications.
Open Robotic assisted p 95% CI Odds
ratio
N % N %
Total complications 47 29.3 11 6.7 <0.001 2.9e11.7 5.82
DVT 2 1.3 0 0.0 0.242 d d
PE 1 1.0 1 1.0 >0.99 0.1e16.6 1.03
Pneumonia 2 1.0 1 1.0 0.618 0.2e23.1 2.08
Ileus 14 9.0 2 1.0 0.002 1.7e35.0 7.82
Bowel obstruction 2 1.0 0 0.0 0.242 d d
Hemorrhage 7 4.0 2 1.0 0.1 0.8e18.2 3.73
Wound infection 10 6.0 2 1.0 0.016 1.2e25.2 5.43
Intraoperative
injurya
2 1.0 0 0.0 0.242 d d
Atelectasis 6 4.0 0 0.0 0.014 d d
Bladder atony 1 1.0 2 1.0 >0.99 0.05e5.7 0.51
Renal failure 0 0.0 1 1.0 >0.99 d d
CI ¼ conﬁdence interval; DVT ¼ deep vein thrombosis; PE ¼ pulmonary embolus.
a One intraoperative enterotomy and one intraoperative ureteral injury.
Table 3
Disease-related survival characteristics.
Open Robotic assisted p
N % N %
Recurrences 10 6 11 7 0.879
Deaths from disease 4 3 6 4 0.75
N Mean N Mean p
Average months to recurrence 10 19.4 10 18.5 0.865
Average months to death 4 23.9 6 22.1 0.704
Open (%) Robotic assisted (%) p
Projected 5-y PFS 93 92 0.8112
Projected 5-y OS 97 96 0.5094
OS ¼ overall survival; PFS ¼ progression-free survival.
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staging. We chose to directly compare outcomes in patients who
could have been staged using either surgical modality. Multiple
centers have shown transvaginal removal of uteri with a mean
weight of > 480 g to be feasible.9 Given this, we chose 480 g as our
cutoff for analysis. We also desired to compare outcomes associated
with the use of minimally invasive staging for early stage endo-
metrioid adenocarcinoma of the uterus at our practice with those
reported in trials, predominantly performed at large, fellowship-
associated, academic centers.2e4 We limited our analysis to pa-
tients with Stage I endometrial cancer as this comprised the ma-
jority of our patient population and a disproportionate number of
patients in Stages IIeIV were staged using laparotomy. Although a
comparison between laparoscopic, robotic, and open approaches to
endometrial cancer staging would be useful, none of the surgeonsFigure 1. Projected 5-year survival curve.
Figure 2. Projected 5-year overall survival curve.
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cancer.
Our perioperative outcomes following both laparotomy and
robot-assisted staging were similar to those reported from large
academic institutions. Gaia et al4 performed a systemic review of
ﬁve comparative studies between laparotomy and robotic-assisted
staging of endometrial cancer. In their study, robotic-assisted
staging was associated with an average EBL of 101 mL and
average length of hospital stay (LOS) of 1.2 days. Laparotomy was
associated with an average EBL of 291 mL and average LOS of 3.9
days. Our LOS for robotic-assisted staging (1.4 days) and laparotomy
(3 days) and EBL during robotic-assisted staging (103.8 mL) and
laparotomy (246mL) were similar to the comparative data reported
by Gaia et al.4 The overall postoperative complication (6.7% robotic
and 29.3% laparotomy) and wound infection (1.2% robotic and 6.2%
laparotomy) rates were similar to other reports from predomi-
nantly academic centers.7,10,11 Lastly, our rate of conversion from
robotic-assisted staging to laparotomy was similar to previously
published studies.12
Although our study was not powered for survival analysis, we
found no difference in relapse-free survival or time to recurrence
between the robotic-assisted and laparotomy cohorts. The two
cohorts were similar in stage, tumor grade and size, depth of in-
vasion, and presence of lymphovascular space invasion. Both co-
horts were also similar in adjuvant therapy received. Recurrence-
free survival of early stage endometrial endometrioid adenocarci-
noma was similar to data from previous retrospective studies
comparing robotic-assisted staging with laparotomy at 3 years
(89.3% and 85.2%),2,3 as well as that found in LAP2 (89.8%).13 There
was also no difference in disease-speciﬁc survival between the two
cohorts, similar to previously published data on 3-year disease-
speciﬁc survival following robotic-assisted staging, which were
92.5% and 94.2%, respectively.2,3 Our projected 5-year progression-
free (92%) and overall survival (97%) following robotic-assisted
were also similar to previously published data.3
One of the major differences between our results and previously
published studies comparing robotic-assisted staging with lapa-
rotomy was the number of lymph nodes sampled. In their
comparative study, Gaia et al4 reported a nonsigniﬁcant increase in
pelvic and para-aortic lymph node yield by robotic-assisted staging
compared with laparotomy (18.0 vs. 14.5 and 9.4 vs. 5.7, respec-
tively). Compared with the data from larger academic institutions,7
less number of pelvic and periaortic nodes were sampled from both
staging modalities in this study; laparotomy resulted in higher
yields for both pelvic nodes (8.4 vs. 6.2, p ¼ 0.003) and periaortic
nodes (1.6 vs. 0.95, p ¼ 0.002) compared with robotic-assistedstaging. The low lymph node yield is interesting given the data
from our clinic published in 2009 showing a pelvic lymph node
count of 17.8/patient when sent separately to pathology as common
iliac, external iliac, internal iliac, and obturator nodes, a practice we
have continued.14 Although age and BMI can be a determinant in
the lymph node count,15 both the average BMI and age of our pa-
tients were similar for patients staged robotically and by laparot-
omy. Despite the fact that the lymph node count differed between
prior studies and modalities, it did not affect relapse-free or overall
survival in our population.
The costs associated with robotic, laparoscopic, and abdominal
hysterectomy have been studied extensively. While robotic hys-
terectomy has been shown to be less costly than abdominal
hysterectomy in multiple studies,6,16 we believe the true coste
beneﬁt lies in the decreased complications associated with ro-
botic hysterectomy compared with an abdominal approach. Our
data show that abdominal hysterectomy signiﬁcantly increases
postoperative ileus, wound infection, and blood loss of > 500 mL.
Postoperative ileus signiﬁcantly increases hospital costs by >
$8000 in patients who underwent colectomy.17 According to a
Centers for Disease Control and Prevention estimate, the average
costs of surgical site infection ranges between $10,443 and
$25,546.18 Lastly, blood loss and transfusion are associated with
increased surgical costs.19 Given the signiﬁcant costs of the
morbidity associated with abdominal hysterectomy, an analysis
of cost, including surgical complications, may further widen the
cost difference between the two approaches. Laparoscopic sur-
gical staging of endometrial cancer is associated with the least
cost and a similar complication rate but we were not able to
include this in our analysis as no surgeons perform laparoscopic
staging at our institution.16
The strengths of our study are the ability to directly compare
both short- and long-term outcomes, uniformity of adjuvant
treatment and surgical protocols, treatment at a single institution,
and the relatively large number of patients. Our main weakness is
the retrospective nature of this study. Complications may not have
been documented in discharge summaries, operative reports, or
ofﬁce notes; or simply not scanned into ofﬁce records. We practice
at two different hospital systems that used paper medical records
until 2007 and now use different electronic medical records sys-
tems, which have changed over the past few years. This made us
mainly reliant on records that were scanned into our electronic
medical system in our ofﬁce at the time of surgery or treatment. We
also did not collect data on quality of life, return to activities of daily
living, or return to work following hysterectomy, where we feel the
true beneﬁt of minimally invasive surgery lies.
This study conﬁrms the well-documented excellent periopera-
tive outcomes following robotic-assisted staging and also contrib-
utes to a growing body of literature providing further evidence that
robotic-assisted staging is not associated with inferior relapse-free
and overall survival compared with laparotomy. Furthermore, our
data conﬁrm that signiﬁcantly less intraoperative EBL, shorter LOS,
less postoperative complications, and fewer wound infections
following robotic-assisted staging for early stage endometrial
adenocarcinoma occur in a private practice setting.References
1. Ramirez PT, Adams S, Boggess JF, Burke WM, Frumovitz M, Gardner GJ, et al.
Robotic-assisted surgery in gynecologic oncology: a Society of Gynecologic
Oncology Consensus Statement. Developed by the Society of Gynecologic
Oncology's Clinical Practice Robotics Task Force. Gynecol Oncol. 2012;124:
180e184.
2. Kilgore JE, Jackson AL, Ko EM, Soper JT, Van Le L, Gehrig PA, et al. Recurrence-
free and 5-year survival following robotic-assisted surgical staging for endo-
metrial carcinoma. Gynecol Oncol. 2013;123:49e53.
M.A. Ulm et al. / Gynecology and Minimally Invasive Therapy 5 (2016) 25e29 293. Cardenas-Goicoechea J, Shepherd A, Momeni M, Mandeli J, Chuang L, Gretz H,
et al. Survival analysis of robotic versus traditional laparoscopic surgical staging
for endometrial cancer. Am J Obstet Gynecol. 2014;210:160.e1e160.e11.
4. Gaia G, Holloway RW, Santoro L, Ahmad S, Di Silverio E, Spinillo A. Robotic-
assisted hysterectomy for endometrial cancer compared with traditional
laparoscopic and laparotomy approaches: a systematic review. Obstet Gynecol.
2010;116:1422e1431.
5. Verheijen R, Zweemer R. Robotic surgery for gynaecologic cancer: an overview.
Curr Oncol Rep. 2012;14:544e549.
6. Yu X, Lum D, Kiet TK, Fuh KC, Orr Jr J, Brooks RA, et al. Utilization of and charges
for robotic versus laparoscopic versus open surgery for endometrial cancer.
J Surg Oncol. 2014;107:653e658.
7. Boggess JF, Gehrig PA, Cantrell L, Shafer A, Ridgway M, Skinner EN, et al.
A comparative study of 3 surgical methods for hysterectomy with staging for
endometrial cancer: robotic assistance, laparoscopy, laparotomy. Am J Obstet
Gynecol. 2008;199:360.e1e360.e9.
8. Bonilla DJ, Mains L, Whitaker R, Crawford B, Finan M, Magnus M. Uterine
weight as a predictor of morbidity after a benign abdominal and total lapa-
roscopic hysterectomy. J Reprod Med. 2007;52:490e498.
9. Payne TN, Dauterive FR, Pitter MC, Giep HN, Giep BN, Grogg TW, et al.
Robotically assisted hysterectomy in patients with large uteri: outcomes in ﬁve
community practices. Obstet Gynecol. 2010;115:535e542.
10. Bell MC, Torgerson J, Seshadri-Kreaden U, Suttle AW, Hunt S. Comparison of
outcomes and cost for endometrial cancer staging via traditional laparotomy,
standard laparoscopy and robotic techniques. Gynecol Oncol. 2008;111:
407e411.
11. DeNardis SA, Holloway RW, Bigsby 4th GE, Pikaart DP, Ahmad S, Finkler NJ.
Robotically assisted laparoscopic hysterectomy versus total abdominal hys-
terectomy and lymphadenectomy for endometrial cancer. Gynecol Oncol.
2008;111:412e417.12. ElSahwi KS, Hooper C, De Leon MC, Gallo TN, Ratner E, Silasi DA, et al. Com-
parison between 155 cases of robotic vs. 150 cases of open surgical staging for
endometrial cancer. Gynecol Oncol. 2012;124:260e264.
13. Walker JL, Piedmonte MR, Spirtos NM, Eisenkop SM, Schlaerth JB, Mannel RS,
et al. Recurrence and survival after random assignment to laparoscopy versus
laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic
Oncology Group LAP2 Study. J Clin Oncol. 2012;30:695e700.
14. Santoso JT, Azadi A, Wan J, Handorf C, Coleman RL, Tillmanns TD. Lymph node
counts in uterine cancer: a randomized double blind trial. Gynecol Oncol.
2009;113:159e162.
15. Hareyama H, Ito K, Watanabe S, Hakoyama M, Uchida A, Oku K, et al. Factors
inﬂuencing the number of pelvic and para-aortic lymph nodes removed in
surgical treatment of endometrial and ovarian cancer. Int J Gynecol Cancer.
2012;22:1577e1584.
16. Zakhari A, Czuzoj-Shulman N, Spence AR, Gotlieb WH, Abenhaim HA. Lapa-
roscopic and robot-assisted hysterectomy for uterine cancer: a comparison of
costs and complications. Am J Obstet Gynecol. 2015. http://dx.doi.org/10.1016/
j.ajog.2015.07.004.
17. Asgeirsson T, El-Badawi KI, Mahmood A, Barletta J, Luchtefeld M, Senagore AJ.
Postoperative ileus: it costs more than you expect. J Am Coll Surg. 2010;210:
228e231.
18. Scott II RD. The Direct Medical Costs of Healthcare-Associated Infections in U.S.
Hospitals and the Beneﬁts of Prevention. Atlanta, GA: Division of Healthcare
Quality Promotion, National Center for Preparedness, Detection and Control of
Infectious Diseases Coordinating Center for Infectious Diseases, Centers for
Disease Control and Prevention; 2009.
19. Stokes ME, Ye X, Shah M, Mercaldi K, Reynolds MW, Rupnow MF, et al. Impact
of bleeding-related complications and/or blood product transfusions on hos-
pital costs in inpatient surgical patients. BMC Health Serv Res. 2011;11:135.
